Dimerix Limited · ASX:DXB
Dimerix — Canaccord Genuity Drug and Device Conference 2026
35 slides from Dimerix's conference presentation, Oct 12, 2026
Slide 1: Dimerix presentation for Canaccord Drug and Device 2026 Conference and Hong Kong meetings
For Immediate Release DIMERIX PRESENTATION FOR CANACCORD DRUG AND DEVICE 2026 CONFERENCE AND HONG KONG MEETINGS For personal use only MELBOURNE, Australia, 12 October 2026: Dimerix Limited (ASX: DXB, “Dimerix”), a clinical-stage biopharmaceutical company developing treatments for kidney disease, is
Slide 2: About Dimerix
About Dimerix Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The Company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis
Slide 3: Dimerix Forward Looking Statement and References
Phase 2 trial and all manufacturing methodology. The Phase 2 trial is designed to investigate DMX-652’s potential to prevent kidney injury and preserve renal function. Dimerix Forward Looking Statement This release includes forward-looking statements that are subject to risks and uncertainties. Alth
Slide 4: Developing new therapies to treat kidney diseases with unmet clinical needs
rsonal use only Developing new therapies to treat kidney diseases with unmet clinical needs Investor Presentation October 2026 Authorised for lodgement by the Board of the Company
Slide 5: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected rsonal use only in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these ex
Slide 6: Dimerix: multiple potential inflection points with clear, value-defining catalysts
Dimerix: multiple potential inflection points with clear, value-defining catalysts A late-stage Phase 3 lead program, a complementary Phase 2-ready asset and an expanding long-term commercial strategy rsonal use only CLINICAL PIPELINE & VALUE DRIVERS THE INVESTMENT CASE DMX-200 PHASE 3 NEX T P OT EN
Slide 7: DMX-200: Phase 3 Global Opportunity
DMX-200: Phase 3 Global Opportunity GLOBAL COMMERCIAL FOOTPRINT PHASE 3: EXECUTION WITH EVIDENCE rsonal use only Reduced risk 5 commercial partners1 EU, Canada, ANZ Greater China, South Korea, Southeast Asia Recruitment complete DMX-200 licensed across major 1 Global Phase 3 ACTION3 trial in pharmac
Slide 8: Cycle of damage in glomerular diseases
Cycle of damage in glomerular diseases FSGS at a glance Existing blood pressure medication Glomeruli exposed to stress rsonal use only 1 FOCAL from high blood pressure DMX-200 Some 1 High blood pressure 2 SEGMENTAL causes hyperfiltration within filter units sections (glomeruli) of the 2 Constant pre
Slide 9: European Renal Association Posters 2025: Phase 3 clinical trial
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=333) rsonal use only Background Phase 3 Trial Timeline Open Label Extension Successful interim anal
Slide 10: DMX-200: partnerships creating diversified revenue potential
DMX-200: partnerships creating diversified revenue potential P O T ENT IAL V ALU E BY T IMING RECEIVED / CONTRACTED NEARER-TERM POTENTIAL LONGER-TERM POTENTIAL UP TO rsonal use only A$318m A$81m + A$237m + A$1.56bn A$1.9bn upfront + potential Upfront fees Pre-launch milestones Post-launch milestones
Slide 11: DMX-652: Phase 2 in acute kidney injury
DMX-652: Phase 2 in acute kidney injury PHASE 2 COMPLEMENTARY RENAL PIPELINE ASSET STRATEGIC RATIONALE DMX-652 rsonal use only Built to add value KIDNEY INJURY targets USP30, an 1 Early risk reduced2 emerging driver of kidney Substantial development work completed by the injury1 originator; the asse
Slide 12: Why is AKI associated with cardiac surgery
Why is AKI associated with cardiac surgery Currently no approved disease-modifying therapies rsonal use only 1 Cardiac Surgery 2 Ischaemia 3 Reperfusion: restores blood flow to kidney Mitochondria rupture ~26% Healthy mitochondria of patients undergoing cardiac surgery suffer kidney injury kidney da
Slide 13: Proposed phase 2 clinical trial design
Proposed phase 2 clinical trial design A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) rsonal use only Screening/randomisation Treatment phase Follow up • Patients identi
Slide 14: DMX-200 and DMX-652: complementary growth pillars
DMX-200 and DMX-652: complementary growth pillars Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how rsonal use only DMX-200 DMX-652 Focal Segmental Glomerulosclerosis Acute kidney injury associated with (FSGS) rare kidney disease 1 Sh
Slide 15: A clear pathway to potential value creation
A clear pathway to potential value creation Two differentiated programs provide multiple independent opportunities for clinical de-risking, regulatory advancement and potential commercial value creation1 rsonal use only CLINICAL EXECUTION DATA CATALYSTS COMMERCIALISATION READINESS 01 02 03 2026 2027
Slide 16: Corporate overview: Capital position and shareholder snapshot
Corporate overview ASX: DXB | Capital position and shareholder snapshot Cash balance (Jun26)* Market capitalisation¹ Share price¹ rsonal use only $16.2 million $132 million $0.22 S H A R E P R I C E Ordinary shares on Average daily liquidity² TICKER SYMBOL issue¹ 600,396,776 $0.3 million ASX: DXB FU
Slide 17: ESG Statement and contact details
(ASX:DXB) rsonal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environm
Slide 18: Dimerix board
Dimerix board rsonal use only Previous experience: Previous experience: Previous experience: Previous experience: Previous experience: (2) (1) (Faulding)(1) • Senior pharmaceutical executive • Experienced in product • Extensive biotech drug • Experienced executive in • Experienced technology and wit
Slide 19: Dimerix management
Dimerix management rsonal use only Previous experience: Previous experience: Previous experience: Previous experience: (1) • Experienced in product • Experienced finance and • 35 years international experience • Experienced pharmaceutical development, commercial strategy governance executive with in
Slide 20: Medical Advisory Board
Medical Advisory Board rsonal use only Professor of Clinical Trials and Professor of Medicine & Mayer Professor of Renal An attending physician and Renal Physician and Head of Graduated from Haverford Assistant Professor in the Personalized Medicine: Molecular & Cellular Medicine: Department of Dire
Slide 21: Appendix – DMX-200
(ASX:DXB) rsonal use only A P P E N D I X – D M X- 2 0 0
Slide 22: DMX-200 – inflammatory modulator
DMX-200 – inflammatory modulator rsonal use only A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Commercial manufacturing sites established in USA3 1. ASX release and investor presentation 29Jul20 and ASX release 11Mar
Slide 23: DMX-200: unique pharmacology
DMX-200: unique pharmacology • CCR2 activation promotes recruitment of inflammatory 500 Proteinuria (mg/24hours) monocytes to the kidney 400 rsonal use only 300 DMX-200 inhibits CCR21 200 Simultaneous inhibition of * CCR2 and AT1R reduces 100 proteinuria an important • Monocytes promote sclerosis an
Slide 24: DMX-200: Phase 2 met primary endpoint
DMX-200: Phase 2 met primary endpoint Clinically encouraging outcomes achieved for patients,1,2 with no safety concerns noted3 rsonal use only Average reduction of 17% in proteinuria after 16 weeks treatment on DMX-200 versus placebo3 “Any reduction in proteinuria could yield years of preserved nati
Slide 25: DMX-200 Phase 2 effect on inflammatory biomarker
DMX-200 Phase 2 effect on inflammatory biomarker1 Unlike other CCR2 antagonists investigated to date, treatment with DMX-200 reduces the urine concentration of the pro-inflammatory ligand of CCR2 called MCP-12 rsonal use only Average baseline MCP-1 versus Change in MCP-1 over time on average baselin
Slide 26: Adult patient recruitment by territory
adult patient recruitment by territory rsonal use only Trial designed for potential approval globally Recruitment completed (adult population)1 333 Adult patients recruited, randomised and dosed2 Latin America Asia Pacific US / Europe 1. ASX release 15 December 2025; 2. Final numbers of adult patien
Slide 27: DMX-200 intellectual property portfolio
DMX-200 intellectual property portfolio DMX-200 rsonal use only Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date in many territories1 Portfolio 2 Formulation Portfolio 5 Global application3 + Exp.2042 Exp.2045/6 (if granted) Paediatric (if gran
Slide 28: Appendix – DMX-652
(ASX:DXB) rsonal use only A P P E N D I X – D M X- 6 5 2
Slide 29: Introducing DMX-652
Introducing DMX-652 A first-in-class, oral, once-daily USP30 inhibitor for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery rsonal use only Small molecule Convenient dosing Well tolerated Phase 2 ready New chemical entity; oral Convenient dosing schedule to Phas
Slide 30: DMX-652 Pre-clinical data demonstrates efficacy signal
DMX-652 Pre-clinical data demonstrates efficacy signal DMX-652 reduces kidney damage DMX-652 reduces scarring (fibrosis) • The uIRI model replicates the processes of • The UUO model predicts acute to chronic rsonal use only cardiac surgery that cause AKI kidney disease progression. • DMX-652 signifi
Slide 31: Significant unmet need in AKI
Significant unmet need in AKI With no approved disease-modifying therapies, severe consequences for patients, surgeons, and health systems rsonal use only 0 1 in 4 30-50% No approved therapies for the Cardiac surgery patients AKI rate in high-risk patients prevention of cardiac surgery- develop AKI
Slide 32: DMX-652 Phase 1 study met primary endpoint
DMX-652 Phase 1 study met primary endpoint Completed in healthy volunteers: strong safety & pharmacokinetic foundation to support Phase 2 clinical trial rsonal use only 85 0 Up to 200mg 100mg Healthy volunteers No serious adverse events Single dose well tolerated; Once daily x 14 days; received DMX-
Slide 33: DMX-652: first-in-class, best-in-class potential
DMX-652: first-in-class, best-in-class potential Unlike competing programs targeting specific inflammatory or fibrotic pathways, DMX-652 acts on a downstream, convergent driver of kidney injury - making it applicable across causes of AKI rsonal use only 1 3 Only USP30 inhibitor in clinical developme
Slide 34: Competitive/complementary trial landscape in AKI
Competitive/complementary trial landscape in AKI DMX-652's differentiated mechanism of action supports complementary use and the potential for superior or additive outcomes rsonal use only Cellular ischaemia Mitophagy Unicycive Therapeutics modulator Phase 1 UNI-494 Mitochondrial K-ATP channel PAUSE
Slide 35: DMX-652 Intellectual property
DMX-652 Intellectual property DMX-652 The acquisition secures owned composition-of-matter IP, plus exclusive freedom-to-operate rights and regulatory exclusivity rsonal use only ACQUIRED · ASSIGNED TO DIMERIX Composition-of-matter patent family1 2043 19 Directly covers DMX-652 (originally MTX-652) -
Dimerix — Canaccord Genuity Drug and Device Conference 2026 on 6ix